cyclacel.com (CYCC): Company Aggregate Debt

Transcription inhibitor patents protect the developments of Cyclacel Pharmaceuticals (CYCC), although a lack of liquidity weakens this barrier. This chart of the price action for a specific debt instrument, where the indicator is fixed at 0.00, is presented below. The business relies on cellular analysis automation to accelerate testing. Meanwhile, Cyclacel Pharmaceuticals (CYCC) remains sensitive to sanctions and disruptions in the logistics of chemical reagents, which complicates global research.

CYCC Cyclacel, Inc. Company Debts (07/04/2022 - 09/12/2025)

Metric breakdowns and analytics for Cyclacel (CYCC)

- current quotes and average value forecast:

Market Price Cyclacel, Inc.|CYCC - Price Target Chart

- stock exchange capitalization data:

Market Capitalization Cyclacel Pharmaceuticals Inc.|CYCC - Enterprise Value

- business book valuation details:

Net Asset Value per Share Cyclacel|CYCC - Company Book Value|Market Value to Book Value cyclacel.com|CYCC - Company Total Assets

- debt obligations and liquidity statistics:

- earnings and multiples data:

CYCC - Net Profit

Summary company analytics:Cyclacel, Inc., CYCC

Signature product of Cyclacel Pharmaceuticals, Inc.

To objectively assess the operational resilience of Cyclacel Pharmaceuticals (CYCC), investors must analyze the issuer's aggregate credit and bond obligations. The total debt indicator sums all external borrowings, demonstrating how effectively the company finances costly partnership research into cell cycle inhibitors, which in the long term determines the balance between financial stability and the pace of scientific expansion.

Competitors of Cyclacel Pharmaceuticals